Mei Pharma, Inc. MEIP
We take great care to ensure that the data presented and summarized in this overview for MEI Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MEIP
View allLatest Institutional Activity in MEIP
Top Purchases
Top Sells
About MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Insider Transactions at MEIP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2024
|
Steven D Wood |
BUY
Grant, award, or other acquisition
|
Direct |
3,100
+41.56%
|
$9,300
$3.17 P/Share
|
|
May 16
2024
|
James P Flynn |
BUY
Grant, award, or other acquisition
|
Direct |
7,900
+50.0%
|
$23,700
$3.16 P/Share
|
|
Oct 20
2023
|
Funicular Funds, LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
120,600
+16.47%
|
$844,200
$7.0 P/Share
|
|
Oct 20
2023
|
Anson Funds Management LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
179,000
+7.55%
|
$1,253,000
$7.0 P/Share
|
|
Oct 11
2023
|
Funicular Funds, LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
30,000
+5.76%
|
$210,000
$7.0 P/Share
|
|
Oct 11
2023
|
Anson Funds Management LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
50,000
+2.66%
|
$350,000
$7.0 P/Share
|
|
Sep 22
2023
|
Funicular Funds, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
32,040
+6.5%
|
$192,240
$6.85 P/Share
|
|
Sep 22
2023
|
Anson Funds Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
48,060
+5.27%
|
$288,360
$6.85 P/Share
|
|
Sep 21
2023
|
Anson Funds Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
33,600
+3.95%
|
$201,600
$6.46 P/Share
|
|
Sep 21
2023
|
Funicular Funds, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,400
+4.96%
|
$134,400
$6.46 P/Share
|
|
Sep 20
2023
|
Anson Funds Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
120,000
+13.3%
|
$720,000
$6.01 P/Share
|
|
Sep 20
2023
|
Funicular Funds, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
80,000
+16.45%
|
$480,000
$6.01 P/Share
|
|
Feb 28
2023
|
Charles V. Baltic Iii |
BUY
Open market or private purchase
|
Direct |
81,500
+43.52%
|
$0
$0.22 P/Share
|
|
Jul 05
2022
|
Richard G Ghalie Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,196
-22.08%
|
$0
$0.54 P/Share
|
|
Jul 02
2021
|
Daniel P Phd Gold |
SELL
Payment of exercise price or tax liability
|
Direct |
41,320
-9.01%
|
$82,640
$2.94 P/Share
|
|
Jul 02
2021
|
David M Urso President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,825
-33.5%
|
$49,650
$2.94 P/Share
|
|
May 25
2021
|
Daniel P Phd Gold |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.08%
|
$10,000
$2.52 P/Share
|
|
Feb 23
2021
|
Frederick W Driscoll |
SELL
Open market or private sale
|
Direct |
25,000
-40.0%
|
$100,000
$4.03 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 11K shares |
|---|